Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has rejected claims that the agency’s enforcement action against Vimal pan masala advertisements featuring Bollywood actors Shah Rukh Khan and Ajay Devgn amounted to a targeted campaign against the film personalities, stating that the regulatory framework applies uniformly to everyone in the advertising chain.
Speaking publicly on the matter, Mundhe emphasised that the action is not selective enforcement aimed at celebrities but the routine application of existing rules to promoters, advertisers, manufacturers, and sellers alike. The Commissioner’s intervention follows a wave of public attention on the FDA’s recent notices to endorsers of pan masala brands, a product category that has historically occupied a contested space under Indian advertising and tobacco-control law.
According to statements reported by Hindustan Times, Mundhe indicated that the agency is pursuing parallel action against the companies that manufacture and distribute the products, alongside the celebrity endorsers. The framing positions the enforcement as a chain-of-custody regulatory exercise rather than a celebrity-focused operation.
What Happened
The Maharashtra FDA has been pursuing action against advertisements for Vimal pan masala, a brand associated with figures in the broader smokeless tobacco industry. Notices and complaints related to endorsements by Shah Rukh Khan and Ajay Devgn have drawn media attention, with critics and commentators questioning whether the agency was singling out film personalities.
Mundhe’s clarification, as reported, asserts that the regulatory logic extends across the entire advertising chain. By publicly stating that manufacturers, distributors, and sellers are also being pursued, the Commissioner has sought to reframe the enforcement as systemic rather than symbolic.
Why It Matters
The case touches on a recurring fault line in Indian advertising regulation: the question of whether celebrities who endorse products bear meaningful legal and moral responsibility when those products fall into legally restricted or socially contentious categories. India has, in recent years, seen multiple instances of regulatory and legal action aimed at celebrity endorsers of products ranging from sugary beverages to tobacco-adjacent goods, with state FDAs and central bodies periodically invoking advertising code provisions and consumer protection statutes.
The Vimal matter is particularly sensitive because pan masala occupies a regulatory grey zone. While many variants do not contain tobacco or nicotine and are therefore not categorised as tobacco products under existing law, public health advocates have long argued that such brands function as gateways to or proxies for smokeless tobacco consumption, and that their advertising — often featuring high-profile endorsers — glamorises habits associated with significant disease burden.
The Maharashtra FDA’s public defence of its action also carries institutional weight. Indian regulatory agencies have, in past episodes, been accused of backing down when high-profile figures or well-resourced companies push back, either through litigation or through public pressure. Mundhe’s willingness to publicly articulate the rationale for the enforcement suggests the agency is preparing for sustained legal and reputational contest.
Background and Context
Indian advertising restrictions on products linked to tobacco use derive from a combination of statutory and self-regulatory frameworks. The Cable Television Networks (Regulation) Act prohibits the transmission of advertisements that promote the consumption of cigarettes, tobacco products, wine, or other intoxicants. The Advertising Standards Council of India (ASCI) Code, a self-regulatory instrument, places further restrictions on claims and endorsements, including provisions that prohibit celebrities from endorsing products in categories deemed inappropriate or harmful.
Pan masala has repeatedly tested the boundaries of these frameworks. Several states have moved to restrict the sale and advertisement of gutka and certain pan masala products, particularly those containing tobacco or magnesium carbonate. Brands such as Vimal have faced regulatory questions not only for their product formulations but for the high-visibility endorsement strategies that have featured cricket players, film actors, and other public figures.
The Maharashtra FDA’s jurisdiction covers one of India’s largest consumer markets and its most prolific film industry, making its enforcement choices particularly visible. Previous state FDA actions against celebrity endorsements have generated disproportionate media coverage relative to the underlying legal questions, a dynamic that the current episode appears to replicate.
What to Watch Next
Several developments will indicate the durability and direction of the current enforcement posture. First, whether the FDA proceeds with formal prosecution against the named endorsers, or whether the matter is resolved through consent agreements, undertakings, or administrative closure, will signal the agency’s appetite for a precedent-setting case. Second, parallel action against the manufacturing and distribution entities will be a key indicator of whether the chain-wide enforcement claim translates into comparable legal exposure for corporate actors. Third, any judicial intervention — whether through anticipatory relief sought by the endorsers or through public interest litigation by health advocacy groups — will determine how courts interpret the existing advertising code in the specific context of pan masala endorsements. Finally, the response of the ASCI and central regulatory bodies, including any clarification of the line between tobacco products and non-tobacco pan masala, will shape the broader regulatory environment beyond Maharashtra.
Analysis:
The framing of the FDA’s enforcement as a “crackdown” on specific celebrities risks obscuring the structural issue at the heart of the case. Celebrity endorsements carry significant commercial weight in India’s consumer economy, and regulators have argued for years that holding endorsers accountable is necessary to make advertising self-regulation meaningful. Mundhe’s clarification aligns with that institutional logic, whether or not one accepts the underlying premise that endorsers bear direct responsibility alongside manufacturers. The argument has a public-health rationale: if endorsers face no consequences, advertising code restrictions become advisory rather than operative, and the deterrent effect on future endorsements weakens.
The political sensitivity of regulatory action involving high-profile figures has historically made Indian agencies cautious, and the FDA’s public defence of its action suggests the agency anticipates both legal pushback and public-relations challenges. Whether the action proceeds through formal prosecution, consent agreements, or eventual withdrawal will indicate how durable the current enforcement posture is — and whether the agency is prepared to absorb the costs of a high-profile contest with well-resourced defendants.
The case also raises a recurring question about state-level FDA action versus central regulation through bodies like ASCI. India’s advertising enforcement architecture is fragmented, with self-regulatory codes, statutory prohibitions, and state-level enforcement actions operating in parallel and sometimes at cross-purposes. The Maharashtra FDA’s assertion of jurisdiction over a nationally advertised campaign featuring pan masala will test how that fragmentation is resolved, and whether other state FDAs follow suit or hold back.
A further analytical point concerns the product category itself. The legal distinction between tobacco-containing and non-tobacco pan masala has been a persistent loophole that manufacturers have used to continue advertising in formats that would otherwise be restricted. If the FDA’s action is framed around advertising code violations rather than product classification, the enforcement may have a narrower scope than public-health advocates would prefer, leaving the underlying product-category question unresolved.
Conclusion
The Maharashtra FDA’s public defence of its action against Vimal pan masala advertisements represents a routine assertion of regulatory authority dressed in unusually public language. By emphasising that the framework applies to the entire advertising chain, Commissioner Mundhe has sought to depersonalise the enforcement and reinforce the institutional principle that celebrity status does not exempt endorsers from advertising law. Whether that principle survives the inevitable legal and reputational contest that follows will determine whether the current action becomes a precedent or a footnote in the long-running struggle over how India regulates the promotion of contested product categories.
Sources
– https://www.hindustantimes.com/india-news/did-maharashtra-fda-chief-tukaram-mundhe-target-shah-rukh-khan-ajay-devgn-over-vimal-ad-he-clarifies-101787737380869.html
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Hindustan Times – India News — source
